Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Leptin R

Leptin R

Brief Information

Name:Leptin receptor
Target Synonym:CD295,OB receptor,LEPR,HuB219,DB,Leptin Receptor,LEP-R,OB-R,OBR,CD295 Antigen,LEPRD,Receptors, Leptin
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
LER-H5252 Human Human Leptin R / CD295 Protein, Fc Tag
LER-H5252-structure
LER-H5252-sds

Synonym Name

LEPR,CD295,DKFZp686B1731,OBR,Leptin receptor

Background

Leptin receptor (LEPR) is also known as LEP-R, cluster of differentiation 295 (CD295), OB-R and B219, is a single-transmembrane-domain receptor of the gp130 family of cytokine receptors. Leptin receptor exists as homodimer and binds Leptin with high affinity, thus mediates the biological function of the adipocyte-specific hormone Leptin. LEPR is a receptor for leptin (an adipocyte-specific hormone that regulates body weight), and is involved in the regulation of fat metabolism, as well as in a novel hematopoietic pathway that is required for normal lymphopoiesis. Mutations in this protein have been associated with obesity and pituitary dysfunction. Interaction of leptin and leptin receptor is crucial for body weight and bone mass regulation in mammals through hypothalamic effects on satiety and energy expenditure. Meanwhile, research data supports a leptin receptor activation model based on ligand-induced conformational changes.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Metreleptin KTR-103; AC-164594 Approved Amylin Pharmaceutical, Bristol-Myers Squibb Company, Astrazeneca Plc Metreleptin [SHIONOGI], Myalepta EU Lipodystrophy Amryt Pharmaceuticals Dac 2013-03-25 HIV Infections; Diabetes Mellitus, Type 1; Amenorrhea; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Lipodystrophy; Obesity; Lipodystrophy, Familial Partial; Overweight; Fasting; Diabetes Mellitus; Lipomatosis, Multiple Symmetrical Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Mibavademab REGN-4461 Phase 2 Clinical Regeneron Pharmaceuticals Inc Lipodystrophy, Congenital Generalized; Lipodystrophy, Familial Partial; Lipid Metabolism Disorders Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message